Zai Lab Ltd represents values of innovation, collaboration, and patient-centricity. With a corporate philosophy focused on developing and commercializing transformative medicines, Zai Lab aims to improve patients' lives across various therapeutic areas. By nurturing strategic partnerships and leveraging cutting-edge research and development, Zai Lab strives to bring novel treatments to market efficiently and effectively. This commitment to innovation is reflected in Zai Lab's mission to address critical unmet medical needs and enhance healthcare outcomes. Through its dedication to excellence and a patient-driven approach, Zai Lab Ltd emphasizes creating sustainable value for both patients and shareholders.

Zai Lab Ltd is primarily present in China and the United States. With its headquarters in Shanghai, China, Zai Lab has established a strong presence in the Chinese pharmaceutical market. The company focuses on developing innovative medicines for the treatment of cancer and other diseases. In addition to China, Zai Lab has expanded its operations and collaborations in the United States to access global resources and expertise in drug development. Through its presence in these two major markets, Zai Lab aims to provide transformative therapies to patients worldwide.

Zai Lab Ltd, a renowned biopharmaceutical company, has accomplished several significant milestones. Notably, the company's continuous commitment to innovation led to the successful development and commercialization of multiple novel drugs. Zai Lab Ltd also achieved numerous regulatory approvals for its cutting-edge therapies, expanding treatment options for patients worldwide. Furthermore, the company's strategic collaborations with global pharmaceutical leaders have facilitated the advancement of its drug pipeline and enhanced research capabilities. With a strong focus on improving patient outcomes, Zai Lab Ltd has demonstrated remarkable progress in revolutionizing the field of biopharmaceuticals through its innovative approach and consistently achieving critical milestones.

Zai Lab Ltd, founded in 2014, is a renowned biopharmaceutical company based in Shanghai, China. The company primarily focuses on the development and commercialization of innovative drugs in the fields of oncology, autoimmune, and infectious diseases. With a mission to transform patient outcomes, Zai Lab has rapidly emerged as a leader in the Chinese biotech industry. The company's commitment to excellence and dedication to scientific advancements are reflected in its robust pipeline of novel therapies. Leveraging its deep understanding of the Chinese market, Zai Lab collaborates with global partners to bring innovative medicines to patients, ensuring access to cutting-edge treatments across various therapeutic areas.

Some of the main competitors of Zai Lab Ltd in the market include BeiGene Ltd, Hutchison China MediTech Limited (Chi-Med), and Innovent Biologics, Inc.

Zai Lab Ltd is primarily active in the biopharmaceutical industry.

The business model of Zai Lab Ltd primarily revolves around developing and commercializing innovative therapies and treatment options in the biopharmaceutical industry. With a focus on discovering, acquiring, and developing differentiated medicines, Zai Lab aims to address critical unmet medical needs in areas such as oncology, autoimmune disorders, and infectious diseases. By leveraging strategic partnerships, collaborations, and licensing agreements, Zai Lab seeks to bring novel therapies to market efficiently and effectively. With a commitment to improving patient outcomes and providing value to stakeholders, Zai Lab combines research, development, and commercialization efforts to drive sustainable growth in the biopharmaceutical sector.

Zai Lab KGV ir -9,01.

Zai Lab KUV ir 6,88.

AlleAktien kvalitātes vērtējums Zai Lab ir 4/10.

gaidāmā Zai Lab apgrozījums ir 396,07 milj. USD.

gaidāmā Zai Lab peļņa ir -302,62 milj. USD.

Zai Lab Ltd. is a biopharmaceutical company founded in China that focuses on researching, developing, and marketing innovative medicines. Its business model is centered around three main areas: oncology, autoimmune diseases, and infectious diseases. Zai Lab is developing therapies for various types of cancer such as lung, liver, stomach, colon, breast, and pancreatic cancer. It also develops treatments for autoimmune diseases like rheumatoid arthritis, lupus, and Crohn's disease. Additionally, Zai Lab focuses on developing medications for infectious diseases like hepatitis B and C, HIV, and COVID-19. The company has partnerships with Novartis, Tesaro, and Sanofi to collaborate on the development and marketing of innovative therapies. Zai Lab has invested in expanding its manufacturing facilities and aims to increase its presence in other parts of Asia and the global market. It has a strong pipeline of drug candidates in various clinical phases.

Zai Lab izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Zai Lab vai uzņēmums nedod dividendes.

Zai Lab ISIN ir KYG9887T1085.

Zai Lab WKN ir A2DX7H.

Zai Lab simbols ir 9688.HK.

Pēdējo 12 mēnešu laikā Zai Lab maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Zai Lab plāno maksāt dividendes 0 USD apmērā.

Zai Lab pašreizējā dividendu rentabilitāte ir .

Zai Lab maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Zai Lab pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Zai Lab tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Zai Lab apmērā 0 USD, kas tika izmaksāta 28.11.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 28.11.2024..

Pēdējās dividendes izmaksa notika 28.11.2024..

Gadā 2023, Zai Lab izmaksāja 0 USD dividendes.

Zai Lab dividendes tiek izmaksātas USD.